Resistance to Molecular Therapies for Hepatocellular Carcinoma
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Cham :
Springer International Publishing : Imprint: Springer,
2017.
|
| Σειρά: | Resistance to Targeted Anti-Cancer Therapeutics,
13 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma
- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma
- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance
- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance
- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma
- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma
- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma
- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
